This category page covers biotechnology and pharmaceutical companies developing therapies that target neuroinflammation in Alzheimer's disease. Neuroinflammation is increasingly recognized as a central driver of neurodegenerative processes, and multiple therapeutic approaches are under development targeting different aspects of the inflammatory cascade.
The main mechanisms being targeted include:
- NLRP3 inflammasome inhibition
- TREM2 modulation on microglia
- TNF-alpha inhibition
- Complement system inhibition
- Microglia modulation
- Focus: NLRP3 inflammasome inhibition
- Lead Candidate: NT-0796
- Indication: Alzheimer's disease
- Stage: Phase 1/2
- Mechanism: Brain-penetrant NLRP3 small molecule inhibitor
- Notes: First-in-class oral therapy targeting neuroinflammation at its source
- Focus: NLRP3 inflammasome inhibition
- Lead Candidate: Dapansutrile (OLT1177)
- Indication: Alzheimer's disease
- Stage: Phase 2
- Mechanism: Oral NLRP3 inhibitor
- Notes: Established safety profile in inflammatory conditions
- Focus: Selective soluble TNF-alpha inhibition
- Lead Candidate: XPro1595
- Indication: Alzheimer's disease (MCI)
- Stage: Phase 2
- Mechanism: Dominant-negative inhibitor of soluble TNFα (preserves membrane-bound TNF)
- Trial ID: NCT05318937
- Notes: Targets neuroinflammation without compromising immune surveillance
- Focus: TREM2 agonism and progranulin modulation
- Lead Candidates: AL002 (TREM2 agonist), AL101 (progranulin)
- Indication: Alzheimer's disease
- Stage: Phase 2
- Mechanism:
- AL002: TREM2 agonist with Alector Brain Carrier (ABC) platform
- AL101: Progranulin antibody to increase progranulin levels
- Partners: Roche (AL002), GSK (AL101)
- Notes: Pioneer in immuno-neurology approach, targeting microglia dysfunction
- Focus: TREM2 agonism
- Lead Candidate: VIG-100
- Indication: Alzheimer's disease
- Stage: Phase 1
- Mechanism: TREM2 activating antibody
- Notes: Focused specifically on TREM2 target
- Focus: TREM2 and lysosomal function
- Lead Candidates: DNL919 (TREM2 agonist), DNL593 (progranulin modulator)
- Indication: Alzheimer's disease, Parkinson's disease
- Stage: Phase 1
- Mechanism: Engineered antibodies with Brain Transport Vehicle (BTV) delivery platform
- Notes: Strong foundation in lysosomal biology and neurodegenerative disease
- Focus: C1q inhibition (classical complement pathway)
- Lead Candidates: ANX005, ANX007
- Indication: Alzheimer's disease (potential)
- Stage: Phase 2 (HD), expanding to AD
- Mechanism: Anti-C1q monoclonal antibody
- Notes: Targets complement-mediated synaptic pruning and neuroinflammation
- Focus: TREM2 and tau targeting
- Lead Candidate: PRX005
- Indication: Alzheimer's disease
- Stage: Phase 1
- Mechanism: Anti-tau antibody with microglial modulation
- Notes: Targets both pathological tau and microglial function
- Focus: Neuroinflammation modulation
- Lead Candidate: SavaRx
- Indication: Alzheimer's disease
- Stage: Phase 3
- Mechanism: Novel mechanism targeting neuroinflammation
- Notes: Late-stage development with potential for approval
- Focus: Microglial modulation
- Lead Candidate: Lu AF20513
- Indication: Alzheimer's disease
- Stage: Phase 1
- Mechanism: Amyloid/TREM2 targeting vaccine
- Notes: Combination approach targeting both amyloid and microglia
| Company |
Drug |
Mechanism |
Phase |
Indication |
| Nodthera |
NT-0796 |
NLRP3 inhibitor |
Phase 1/2 |
AD |
| INmune Bio |
XPro1595 |
Anti-sTNFα |
Phase 2 |
AD (MCI) |
| Alector |
AL002 |
TREM2 agonist |
Phase 2 |
AD |
| Alector |
AL101 |
Progranulin |
Phase 2 |
AD |
| Vigil Neuroscience |
VIG-100 |
TREM2 agonist |
Phase 1 |
AD |
| Denali Therapeutics |
DNL919 |
TREM2 agonist |
Phase 1 |
AD |
| Annexon |
ANX005 |
C1q inhibitor |
Phase 2 |
HD→AD |
| Prothelia |
PRX005 |
Anti-tau/microglia |
Phase 1 |
AD |
| Cassava Sciences |
SavaRx |
Neuroinflammation |
Phase 3 |
AD |
| Olatec |
Dapansutrile |
NLRP3 inhibitor |
Phase 2 |
AD |
Chronic neuroinflammation in Alzheimer's disease involves multiple interconnected pathways:
- Amyloid-beta deposition activates microglia
- NLRP3 inflammasome assembles in activated microglia
- Pro-inflammatory cytokines (IL-1β, IL-18, TNFα) are released
- Tau phosphorylation is enhanced by inflammatory mediators
- Synaptic dysfunction and neuronal loss result
| Mechanism |
Target |
Companies |
Development Stage |
| NLRP3 Inhibition |
Inflammasome assembly |
Nodthera, Olatec |
Phase 1-2 |
| TNF-α Inhibition |
Soluble TNF signaling |
INmune Bio |
Phase 2 |
| TREM2 Agonism |
Microglial activation |
Alector, Vigil, Denali |
Phase 1-2 |
| Complement Inhibition |
C1q-mediated pruning |
Annexon |
Phase 2 |
| Microglia Modulation |
CSF1R, CX3CR1 |
Lundbeck, Prothelia |
Phase 1-3 |
¶ Clinical Trial Landscape
| Company |
Drug |
NCT Number |
Phase |
Status |
| INmune Bio |
XPro1595 |
NCT05318937 |
Phase 2 |
Recruiting |
| Nodthera |
NT-0796 |
NCT05632433 |
Phase 1/2 |
Recruiting |
| Alector |
AL002 |
NCT05139056 |
Phase 2 |
Active |